All Oncology News

Alex A. Adjei, MD, PhD, a professor of oncology and pharmacology at Mayo Clinic, discussed the history of five target genes: NTRK, RET, MET, BRAF, and HER2, as well as the exciting data coming out for the lung cancer subset.

Toni Choueiri, MD, discusses the rationale behind the Kidney Cancer Research Summit and recent advances in the renal cell carcinoma landscape.

Shubhada Dhage, MD, FACS, discusses the role of surgery and other therapeutic modalities in breast cancer and explained the shift toward de-escalated treatments and less morbid surgical management strategies.

Naomi Fujioka, MD, discusses the clinical implications of the PACIFIC trial in NSCLC treatment and additional questions that are informing planned and ongoing trial designs in stage III disease.

Adding daratumumab to carfilzomib and dexamethasone improved progression-free survival in patients with relapsed/refractory multiple myeloma, according to topline findings from the phase III CANDOR study.

Gary H. Lyman, MD, MPH, discusses the current parameters used to develop a biosimilar, the impact these products have had in the treatment and supportive care settings, and ongoing initiatives to address remaining challenges.

Joseph Leach, MD, a medical oncologist at Minnesota Oncology, discussed the emergence of ALK inhibitors in lung cancer and the importance of testing for such molecular abnormalities.

Joshua P. Sasine, MD, PhD, spotlights some of the strategies under investigation to improve the safety and efficacy of CAR T-cell therapy in hematologic malignancies.

The FDA has granted a priority review designation to a biologics license application for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who have received prior treatment with a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced, or metastatic setting.

Ochsner Cancer Institute (Ochsner), along with its Gulf South NCI Community Oncology Research Program (NCORP) partners, has been awarded a $13.6 million grant by the National Cancer Institute to expand the successful statewide clinical trials network with a special emphasis on minority and underserved cancer patients.

The FDA is updating the prescribing information and Patient Package Insert for CDK4/6 inhibitors to include a warning that the treatments in rare cases may cause severe inflammation of the lungs.

A fixed-dose subcutaneous injection of pertuzumab and trastuzumab with hyaluronidase in combination with intravenous chemotherapy demonstrated noninferior pharmacokinetics compared with the standard IV infusions of the regimen in patients with HER2-positive early breast cancer, meeting the primary endpoint of the phase III FeDeriCa trial (NCT03493854).

Treatment with Toca 511 and Toca FC did not improve overall survival compared with standard therapy in patients with recurrent high-grade glioma undergoing resection, missing the primary endpoint of the phase III Toca 5 trial.

Maintenance therapy with CC-486 (oral azacitidine) led to a highly statistically significant and clinically meaningful improvement in overall survival compared with placebo in patients with newly diagnosed acute myeloid leukemia who achieved first complete response or CR with incomplete blood count recovery with induction therapy.

Patients with advanced non–small cell lung cancer and actionable mutations had similar progression-free survival whether treatment guidance came from tissue or circulating tumor (ct)DNA analysis using the Guardant360 assay, a matched retrospective comparison showed.

The investigational Trop-2–targeting antibody-drug conjugate DS-1062 demonstrated antitumor activity in unselected patients with unresectable, advanced non–small cell lung cancer.

Single-agent atezolizumab extended overall survival compared with chemotherapy as a frontline treatment for patients with advanced nonsquamous and squamous non–small cell lung cancer and high PD-L1 expression, according to topline findings from the phase III IMpower110 trial.

Alexander A. Hindenburg, MD, discusses novel agents and ongoing clinical trials supporting their future application in metastatic, hormone receptor–positive, HER2-negative breast cancer.

The FDA has granted a breakthrough therapy designation to the MET inhibitor tepotinib as a treatment for certain patients with metastatic non–small cell lung cancer with MET exon14-skipping alterations.

The FDA has accepted a supplemental new drug application for neratinib for use in combination with capecitabine for the treatment of patients with HER2-positive metastatic breast cancer who have failed at least 2 prior lines of HER2-directed treatments.

Robert A. Kratzke, MD discusses the excitement surrounding immunotherapy and the work being done with biomarkers to assist in making optimal treatment decisions in lung cancer.

Tanya Siddiqi, MD, discusses the novel agents that have emerged in the treatment paradigm for patients with chronic lymphocytic leukemia.

Results from the second prespecified analysis of the TIVO-3 trial showed a hazard ratio for overall survival of 0.99 for tivozanib compared with sorafenib in patients with highly refractory metastatic renal cell carcinoma.

Nina D’Abreo, MD, explains how treatment is being tailored to women with early-stage, HR-positive, HER2-negative breast cancer.

The FDA has granted a fast track designation to AMG 510 for the treatment of patients with KRAS G12C–mutated metastatic non–small cell lung cancer who received prior therapy.

Two distinct subtypes of nonfunctional pancreatic neuroendocrine tumors could help prognosticate risk of recurrence following surgery.

Douglas K. Marks, MD, discusses key developments in the HER2-positive breast cancer space and shed light on novel approaches under investigation.

The question of what the accepted therapeutic strategies for de-intensification in low-risk, HPV-related oropharyngeal squamous cell carcinoma are will be debated in an upcoming discussion.

Lee S. Schwartzberg, MD, discusses the mission of OneOncology as well as the work that is being done to bring biosimilars to the market.

Three months of adjuvant oxaliplatin-based therapy in patients with high-risk, stage II colorectal cancer was found to be inferior to 6 months of treatment.